DC 101

Drug Profile

DC 101

Alternative Names: anti-flk-1 monoclonal antibody; DC101

Latest Information Update: 23 Mar 2009

Price : $50

At a glance

  • Originator ImClone Systems
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Intercellular signalling peptide and protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Mar 2009 Discontinued - Preclinical for Cancer in USA (Injection)
  • 24 Nov 2008 ImClone Systems has been acquired by Eli Lilly
  • 24 Oct 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top